Similar articles for PMID: 33277393

Year	Number of Results
2016	4
2017	7
2018	10
2019	16
2020	26
2021	41
2022	30
2023	19
2024	0

1

Mechanisms of Resistance to Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy in a Mouse Model of Prostate Cancer.

Stuparu AD, Capri JR, Meyer CAL, Le TM, Evans-Axelsson SL, Current K, Lennox M, Mona CE, Fendler WP, Calais J, Eiber M, Dahlbom M, Czernin J, Radu CG, Lückerath K, Slavik R. Stuparu AD, et al. J Nucl Med. 2021 Jul 1;62(7):989-995. doi: 10.2967/jnumed.120.256263. Epub 2020 Dec 4. J Nucl Med. 2021. PMID: 33277393 Free PMC article.

2

Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing ¹⁷⁷Lu-PSMA-617 radioligand therapy.

Khreish F, Kochems N, Rosar F, Sabet A, Ries M, Maus S, Saar M, Bartholomä M, Ezziddin S. Khreish F, et al. Eur J Nucl Med Mol Imaging. 2021 Jan;48(1):103-112. doi: 10.1007/s00259-020-04828-5. Epub 2020 May 6. Eur J Nucl Med Mol Imaging. 2021. PMID: 32378019

3

A Single-Arm, Low-Dose, Prospective Study of ¹⁷⁷Lu-EB-PSMA Radioligand Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer.

Wang G, Zang J, Jiang Y, Liu Q, Sui H, Wang R, Fan X, Zhang J, Zhu Z, Chen X. Wang G, et al. J Nucl Med. 2023 Apr;64(4):611-617. doi: 10.2967/jnumed.122.264857. Epub 2022 Nov 3. J Nucl Med. 2023. PMID: 36328486 Free article.

4

Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer.

Lückerath K, Wei L, Fendler WP, Evans-Axelsson S, Stuparu AD, Slavik R, Mona CE, Calais J, Rettig M, Reiter RE, Herrmann K, Radu CG, Czernin J, Eiber M. Lückerath K, et al. EJNMMI Res. 2018 Oct 29;8(1):96. doi: 10.1186/s13550-018-0451-z. EJNMMI Res. 2018. PMID: 30374743 Free PMC article.

5

Genomic characterization of metastatic castration-resistant prostate cancer patients undergoing PSMA radioligand therapy: A single-center experience.

Satapathy S, Das CK, Aggarwal P, Sood A, Parihar AS, Singh SK, Mittal BR. Satapathy S, et al. Prostate. 2023 Feb;83(2):169-178. doi: 10.1002/pros.24450. Epub 2022 Oct 19. Prostate. 2023. PMID: 36259290

6

177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study).

Khreish F, Ghazal Z, Marlowe RJ, Rosar F, Sabet A, Maus S, Linxweiler J, Bartholomä M, Ezziddin S. Khreish F, et al. Eur J Nucl Med Mol Imaging. 2022 Feb;49(3):1075-1085. doi: 10.1007/s00259-021-05525-7. Epub 2021 Sep 7. Eur J Nucl Med Mol Imaging. 2022. PMID: 34494131 Free PMC article.

7

Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer.

Privé BM, Slootbeek PHJ, Laarhuis BI, Naga SP, van der Doelen MJ, van Kalmthout LWM, de Keizer B, Ezziddin S, Kratochwil C, Morgenstern A, Bruchertseifer F, Ligtenberg MJL, Witjes JA, van Oort IM, Gotthardt M, Heskamp S, Janssen MJR, Gerritsen WR, Nagarajah J, Mehra N. Privé BM, et al. Prostate Cancer Prostatic Dis. 2022 Mar;25(1):71-78. doi: 10.1038/s41391-021-00424-2. Epub 2021 Jul 12. Prostate Cancer Prostatic Dis. 2022. PMID: 34253846

8

Efficacy and safety of ²²⁵Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant Prostate Cancer patients.

Yadav MP, Ballal S, Sahoo RK, Tripathi M, Seth A, Bal C. Yadav MP, et al. Theranostics. 2020 Jul 23;10(20):9364-9377. doi: 10.7150/thno.48107. eCollection 2020. Theranostics. 2020. PMID: 32802197 Free PMC article.

9

Prognostic factors of overall and prostate-specific antigen-progression-free survival in metastatic castration-resistant prostate cancer patients treated with ¹⁷⁷ Lu-PSMA-617. A single-center prospective observational study.

Telli T, Tuncel M, Karabulut E, Aksoy S, Erman M, Akdogan B, Caglar M. Telli T, et al. Prostate. 2023 Jun;83(8):792-800. doi: 10.1002/pros.24518. Epub 2023 Mar 15. Prostate. 2023. PMID: 36919876

10

177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.

Baum RP, Kulkarni HR, Schuchardt C, Singh A, Wirtz M, Wiessalla S, Schottelius M, Mueller D, Klette I, Wester HJ. Baum RP, et al. J Nucl Med. 2016 Jul;57(7):1006-13. doi: 10.2967/jnumed.115.168443. Epub 2016 Jan 21. J Nucl Med. 2016. PMID: 26795286 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

117 results

Results by year